Matches in Wikidata for { <http://www.wikidata.org/entity/Q83807162> ?p ?o ?g. }
Showing items 1 to 37 of
37
with 100 items per page.
- Q83807162 description "clinical trial" @default.
- Q83807162 description "ensayu clínicu" @default.
- Q83807162 description "klinisch onderzoek" @default.
- Q83807162 description "клінічне випробування" @default.
- Q83807162 name "Testing the Addition of Immunotherapy, Pembrolizumab, to the Conventional Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia" @default.
- Q83807162 name "Testing the Addition of Immunotherapy, Pembrolizumab, to the Conventional Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia" @default.
- Q83807162 type Item @default.
- Q83807162 label "Testing the Addition of Immunotherapy, Pembrolizumab, to the Conventional Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia" @default.
- Q83807162 label "Testing the Addition of Immunotherapy, Pembrolizumab, to the Conventional Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia" @default.
- Q83807162 prefLabel "Testing the Addition of Immunotherapy, Pembrolizumab, to the Conventional Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia" @default.
- Q83807162 prefLabel "Testing the Addition of Immunotherapy, Pembrolizumab, to the Conventional Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia" @default.
- Q83807162 P1050 Q83807162-1DC7721A-87C8-401A-861E-9FDAFCFADFAD @default.
- Q83807162 P1132 Q83807162-57B3439D-41B5-4C26-B986-60163D644A13 @default.
- Q83807162 P1476 Q83807162-E95B3B8E-C45A-45A3-9410-D0503DA0851B @default.
- Q83807162 P2899 Q83807162-33B24BC3-983B-464F-8BA9-A6BAF4F6980A @default.
- Q83807162 P3098 Q83807162-03E524C9-B1DC-4D63-A813-A6E87B953681 @default.
- Q83807162 P31 Q83807162-B6DE0481-A12D-4A2B-93F8-E884488F0ABA @default.
- Q83807162 P4844 Q83807162-19317858-868C-4E1F-A9D6-B8671B109C19 @default.
- Q83807162 P4844 Q83807162-9696A4C9-D1F3-4C35-8BFB-E2C47D91F983 @default.
- Q83807162 P4844 Q83807162-ED782FFF-97A0-4346-AA6D-6D7903123B44 @default.
- Q83807162 P580 Q83807162-BD8AC755-3935-44F7-AFD8-AD1DAB968BE4 @default.
- Q83807162 P582 Q83807162-3F94A278-8348-425F-862A-CB85FE6CF5A9 @default.
- Q83807162 P6099 Q83807162-902F36A7-6C2A-4520-ACE5-9FD72FAA9D5B @default.
- Q83807162 P8363 Q83807162-9116D608-41EC-4578-B7CA-B2554C043C3C @default.
- Q83807162 P1050 Q29496 @default.
- Q83807162 P1132 "+124" @default.
- Q83807162 P1476 "Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination With Conventional Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia" @default.
- Q83807162 P2899 "+18" @default.
- Q83807162 P3098 "NCT04214249" @default.
- Q83807162 P31 Q30612 @default.
- Q83807162 P4844 Q1063862 @default.
- Q83807162 P4844 Q13896859 @default.
- Q83807162 P4844 Q180983 @default.
- Q83807162 P580 "2020-01-20T00:00:00Z" @default.
- Q83807162 P582 "2024-07-31T00:00:00Z" @default.
- Q83807162 P6099 Q42824440 @default.
- Q83807162 P8363 Q78089383 @default.